| Q38203819 | Anti-cancer palladium complexes: a focus on PdX2L2, palladacycles and related complexes |
| Q39247606 | Contrasting cellular uptake pathways for chlorido and iodido iminopyridine ruthenium arene anticancer complexes |
| Q39294174 | Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells |
| Q41883625 | Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse. |
| Q38827745 | In vitro and in vivo evaluation of organometallic gold(I) derivatives as anticancer agents. |
| Q38710506 | Is matching ruthenium with dithiocarbamato ligands a potent chemotherapeutic weapon in oncology? |
| Q36952837 | Organometallic Iridium(III) anticancer complexes with new mechanisms of action: NCI-60 screening, mitochondrial targeting, and apoptosis |
| Q58117720 | Osmium-Nitrosyl Oxalato-Bridged Lanthanide-Centered Pentanuclear Complexes - Synthesis, Crystal Structures and Magnetic Properties |
| Q37432620 | Potential anticancer heterometallic Fe-Au and Fe-Pd agents: initial mechanistic insights |
| Q38770155 | Regulating the anticancer properties of organometallic dendrimers using pyridylferrocene entities: synthesis, cytotoxicity and DNA binding studies |
| Q47411821 | Solvent and Copper Ion-Induced Synthesis of Pyridyl-Pyrazole-3-One Derivatives: Crystal Structure, Cytotoxicity |
| Q39178846 | Synthesis and characterization of a new class of anti-angiogenic agents based on ruthenium clusters |
| Q38634005 | Synthesis, Molecular Structure and Cytotoxicity of Molecular Materials Based on Water Soluble Half-Sandwich Rh(III) and Ir(III) Tetranuclear Metalla-Cycles |
| Q39246566 | The influence of RAPTA moieties on the antiproliferative activity of peripheral-functionalised poly(salicylaldiminato) metallodendrimers |
| Q60212382 | Understanding the interactions of diruthenium anticancer agents with amino acids |